Integrated Psychiatric Services

Spravato®

Understanding Spravato®

A Whole-Person Perspective

For some individuals, depression does not improve despite trying multiple antidepressants and therapies. This is known as treatment-resistant depression (TRD) — a condition that can feel frustrating, exhausting, and isolating.

Spravato® (esketamine), an FDA-approved nasal spray, offers a new pathway to relief for adults with TRD and for those experiencing major depressive disorder (MDD) with suicidal thoughts or actions. Unlike traditional antidepressants, Spravato works on different brain pathways and can provide rapid improvement in mood for many patients.

At Integrative Psychiatric Services (IPS), we provide Spravato within a comprehensive treatment plan, combining clinical expertise with compassionate care in a safe, supportive setting.

Spravato in America: Fast Facts

How Spravato Works

Spravato targets the NMDA receptor system in the brain, increasing glutamate — a neurotransmitter involved in mood regulation and neuroplasticity. This action can:

Who is Spravato For?

Spravato may be considered for adults who:

The Spravato Process at IPS

We provide Spravato in a comfortable, private, and medically monitored environment:
Because Spravato can cause temporary side effects such as dizziness or feeling “spaced out,” you will need a ride home after each session.

Typical Treatment Schedule

Possible Side Effects

Most side effects are temporary and monitored closely during each session:

Why Choose IPS for Spravato?

Moving Forward with Hope

Treatment-resistant depression can feel like a closed door, but Spravato offers a new way forward. Many patients describe feeling their mood lift for the first time in years.

At IPS, we’re committed to guiding you through every step — with science-based care, compassion, and a shared belief that recovery is possible
Visited 84 times, 1 visit(s) today